REGN 2Q26: Strong beat across the board, with Dupixent leading the way

研报英文原文证据摘录

REGN 2Q26: Strong beat across the board, with Dupixent leading the way

Jeffrey Walch, MD, Ph.D. +1 917 344 8613 jeffrey.walch@bernsteinsg.com 30 July 2026

To our readers in Australia: Sanford C. Bernstein (Hong Kong) Limited 盛博香港有限公司 is responsible for distributing research

in Australia. It is regulated by the Securities and Exchange Commission under U.S. laws, by the Financial Conduct Authority under

U.K. laws, which differs from Australian laws. Sanford C. Bernstein (Hong Kong) Limited 盛博香港有限公司 is exempt from the

requirement to hold an Australian financial services license under the Corporations Act 2001 in respect of the provision of the

following financial services to wholesale clients:

• providing financial product advice;

• dealing in a financial product;

• making a market for a financial product; and

• providing a custodial or depository service.

To our readers in India: This publication is being distributed in India by Sanford C. Bernstein (India) Private Limited (SCB India)

which is licensed and regulated by Securities and Exchange Board of India ("SEBI") as a research analyst entity under the SEBI

(Research Analyst) Regulations, 2014, having registration no. INH000006378 and as a stock broker having registration no.

INZ000213537. SCB India is currently engaged in the business of providing research and stock broking services. Please refer to

www.bernsteinresearch.in for more information.

• SCB India is a Private limited company incorporated under the Companies Act, 2013, on April 12, 2017 bearing corporate

identification number U65999MH2017FTC293762, and registered office at Level 3A, 4th Floor, First International Financial

Centre, Plot Nos C-54 and C-55, G Block, Near CBI Office, Bandra Kurla Complex, Bandra (East), Mumbai 400098,